Transforming growth factor-β1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity

1998 ◽  
Vol 28 (5) ◽  
pp. 803-811 ◽  
Author(s):  
Elke M. Bayer ◽  
Wolfgang Herr ◽  
Stephan Kanzler ◽  
Christine Waldmann ◽  
Karl-Hermann Meyer Zum Büschenfelde ◽  
...  
Cytokine ◽  
2000 ◽  
Vol 12 (6) ◽  
pp. 811-814 ◽  
Author(s):  
Rodolfo Sacco ◽  
Domenico Leuci ◽  
Cosimo Tortorella ◽  
Giorgio Fiore ◽  
Felice Marinosci ◽  
...  

Author(s):  
Kyoko Okada ◽  
Kenji Hashimoto ◽  
Yasuhide Iwata ◽  
Kazuhiko Nakamura ◽  
Masatsugu Tsujii ◽  
...  

Author(s):  
Eman M. Hamdy ◽  
Nashwa A. Shebl ◽  
Tarek M. Mostafa

Background: Direct-acting antiviral agents therapy is considered a breakthrough in hepatology due to high rates of sustained virologic response in all patients including those with decompensated cirrhosis. However, impact of Direct-acting antiviral agents-induced sustained virologic response on hepatocellular carcinoma development remains conflicting. Aims: This study aimed at evaluating the change in circulating levels of vascular endothelial growth factor and transforming growth factor-β1, the main angiogenic factors involved in hepatocarcinogenesis process, in cirrhotic patients achieved sustained virologic response after Direct-acting antiviral agents therapy. Study Design: This was a prospective, single-center, cohort study. Place and Duration of Study: Patients were recruited from the outpatient clinic of National Liver Institute, which considered a tertiary referral center in Menoufia University, Egypt (September 2018 to February 2019). Methodology: Forty-five decompensated cirrhotic hepatitis C virus infected patients with no history of hepatocellular carcinoma participated in the study. All patients received 60mg oral daclatasvir and 400mg oral sofosbuvir once daily for 12 or 24 weeks with or without ribavirin. Serum levels of vascular endothelial growth factor and transforming growth factor-β1 were measured at baseline and 12 weeks after the end of therapy. Results: The median serum levels of vascular endothelial growth factor showed a non-statistically significant increase (from 1123 ng/L to 1269 ng/L, P = 0.126). But, transforming growth factor-β1 median serum levels exhibited a non-statistically significant reduction (from 13.22 ng/ml to 12.44 ng/ml, P = 0.163) 12 weeks after treatment. Conclusion: Our findings show direct-acting antiviral agents therapy do not affect vascular endothelial growth factor and transforming growth factor-β1 serum levels. But, a larger scale prospective cohort study on an extended follow-up period is recommended.


2010 ◽  
Vol 124 (9) ◽  
pp. 990-994 ◽  
Author(s):  
S Rota ◽  
I Fidan ◽  
T Muderris ◽  
E Yesilyurt ◽  
Z Lale

AbstractObjective:Some researchers have suggested that Epstein–Barr virus may play a role in the pathogenesis of laryngeal malignancies. In order to clarify the role of cytokines in this disease context, the current study aimed to determine the serum levels of cytokines in Epstein–Barr virus DNA positive patients with laryngeal carcinoma.Subjects:The study included 10 patients with diagnosed laryngeal carcinoma and Epstein–Barr virus DNA positive tumour tissue samples. The control group comprised 10 Epstein–Barr virus DNA negative patients diagnosed with laryngeal carcinoma, 10 patients with acute Epstein–Barr virus infection and 10 healthy individuals.Method:Serum cytokine levels were determined by enzyme-linked immunosorbent assay.Results:The Epstein–Barr virus DNA positive and negative laryngeal carcinoma patients showed no differences regarding serum levels of the following cytokines: interleukins 1β, 2, 6 and 12, tumour necrosis factor α, and interferon γ. However, serum levels of interleukin 10 and transforming growth factor β1 were significantly higher in Epstein–Barr virus DNA positive laryngeal carcinoma patients compared with Epstein–Barr virus DNA negative laryngeal carcinoma patients (p < 0.05).Conclusion:Our results suggest that the cytokines interleukin 10 and transforming growth factor β1 may act as growth factors in Epstein–Barr virus related laryngeal carcinoma. These cytokines may thus represent potential targets for molecular therapeutic treatment for laryngeal carcinoma; they may also be useful as indicators of disease prognosis.


Sign in / Sign up

Export Citation Format

Share Document